[1]    Polyphyllin D Punctures Hypertrophic Lysosomes to Reverse Drug Resistance of Hepatocellular Carcinoma by Targeting Acid Sphingomyelinase. Wang, Y. ¹, Chen, Y.Y.¹, Gao, G.B.¹, Zheng, Y.H., Yu, N.N, Ouyang, L., Gao, X.J., Li, N., Wen, S.Y., Huang, S.J., Zhao, Q., Liu, L.X., Cao, M.R., Zhang, S.X. *,Zhang, J.*, He, Q.Y.*. Molecular Therapy. 2023 Jul 5;31(7):2169-2187.（Corporate Communications）

[2]    Histone deacetylase inhibitor pracinostat suppresses colorectal cancer by inducing CDK5-Drp1 signaling-mediated peripheral mitofission. Liang, X.L. ¹, Ouyang, L. ¹, Yu, N.N, Sun, Z.H., Gui, Z.K., Niu, Y.L., He, Q.Y.*， Zhang, J.*, Wang, Y.*. Journal of Pharmaceutical Analysis. 2023 Oct;13(10):1168-1182. （Corporate Communications）

[3]    A hypoxia-derived gene signature to suggest cisplatin-based therapeutic responses in patients with cervical cancer. Fang J¹, Wang Y¹, Li C¹, Liu W, Wang W, Wu X, Wang Y*, Zhang S*, Zhang J*. Computational and structural biotechnology journal 2024, 23:2565-2579.（Corporate Communications）

[4]    Pan-cancer analysis identifies venous thromboembolism-related genes F3, PLAT, and C1S as potential prognostic biomarkers for glioblastoma and lower grade glioma.Zhang J^1,*, Zhao Q¹, Du Y¹, Wang W, Liu C*.Mol Biomed 2024, 5(1):34.（monograph-cum-newsletter）

[5]    C20orf24 promotes colorectal cancer progression by recruiting Rin1 to activate Rab5-mediated mitogen-activated protein kinase/extracellular signal-regulated kinase signalling. Wang, Y.¹, Zhang, J.¹, Huang, Z.H., Huang, X.H., Zheng, W., Yin, X.F., Li, Y.L., Li, B.*, He, Q.Y.*. Clinical and Translational Medicine. 2022 Apr;12(4):e796.（collaborative effort）

[6]    Alteration of mitochondrial protein succinylation against cellular oxidative stress in cancer. Zhang, J.¹, Han, Z.Q., Wang, Y. *, & He, Q.Y.*. Military Medical Research. 2022 Feb 4;9(1):6.（only work）

[7]    Has-miR-335 enhances cell migration and invasion in lung adenocarcinoma through targeting Copine-1. Wang, Y.¹, Zhang, J.¹, Zhong, L.Y.¹, Huang, S.J., Yu, N.N., Ou, Y.L., Niu, Y.L., Chen, J.X., Lu, C.H., He, Q.Y.*. MedComm. 2021;1-11.（collaborative effort）

[8]    Curcumol Overcomes TRAIL Resistance of Non-Small Cell Lung Cancer by Targeting NRH: Quinone Oxidoreductase 2 (NQO2). Zhang, J. ¹, Zhou, Y., Li, N., Liu, W.T., Liang, J.Z., Sun, Y., Zhang, W.X., Fang, R.D., Huang, S.L., Sun, Z.H., Wang, Y.*, He, Q.Y.*. Advanced Science. 202002306.（only work）

[9]    Structure-based discovery of neoandrographolide as a novel inhibitor of Rab5 to suppress cancer growth. Zhang, J.¹, Sun, Y.¹, Zhong, L.Y., Yu, N.N, Ouyang, L., Fang, R.D, Wang, Y.*, He, Q. Y.*. Computational and Structural Biotechnology Journal, 18 (2020) 3936–3946. （collaborative effort）

[10]A hidden human proteome encoded by 'non-coding' genes. Lu, S.H.¹,Zhang, J.¹, Lian, X.L.¹, Sun, L., Meng, K., Chen, Y., Sun, Z.H., Yin, X.F., Li, Y.X, Zhao, J., Wang, T.*, Zhang, G.*, He, Q.Y.*. Nucleic acids research, 2019, 47(15): 8111-8125.（collaborative effort）

Software copyrights

[1] Online Platform for Predicting and Analyzing Protein Sequences of Genome-unknown Species V1.0；dated 20241224；registration number 2024SR2178757

[2] Machine Learning Model for Predicting Protein Sequences of Genome-unknown Species XPro-NG Software V1.0； dated 20241224； registration number 2024SR2178788

Research Programs

[1] National Key Research and Development Program-Subtopic, 2023YFF1204600, Research and Development of Key Technology for Acquisition and Analysis of Lack of Oxygen Phenotype Information of Nasopharyngeal Carcinoma, 2023-11 to 2026-10, 1.8 Million, Presided over, under research.

[2] National Key Research and Development Program-Subtopic, 2023YFA1304600, Research on New Technologies for Precise Ab initio Sequencing of Proteins and Peptides at the Histological Scale, 2022-12 to 2027-11, 300,000, presided, under research.

[3] Guangdong Provincial Fundamental and Applied Basic Research Fund Project-Provincial Enterprises Joint Fund, Top Project, 2022A1515220212, LncPRXL2B encodes a novel protein MMAP regulating mitochondrial function and metabolic reprogramming in lung adenocarcinoma cells, 2022-11 to 2025-10, 150,000, presided, under research.

[4] Guangzhou Basic and Applied Basic Research Topic, 2024A04J4183, Mechanism study on the inhibition of colorectal cancer through inducing mitochondrial peripheral shear by the deacetylase inhibitor pracinostat, 2024-01 to 2025-12, 50,000, presided, under research.

[5] Project of Basic Research Operating Costs of the Central Universities, JIU Science and Technology Association 2024 Young Scientific and Technological Talents Support Project, First Level, 21624205, 2024-01 to 2025-12, 200,000, presided over, under research.

[6] Project of Basic Research Operating Costs of the Central Universities, Cross-disciplinary Cultivation Special Project, 21622110, Cancer Inhibition Function and Clinical Research of Novel Protein SMIM26, 2022-04 to 2024-04, 300,000, co-chairing, completed.

[7] National Foundation of China, Youth Project, 82002948, Phosphorylation Regulation Mechanism of HnRNPC and its Role in Promoting Colorectal Cancer Stemming, 2021-01 to 2023-12, 0.24 million, presided over, completed.

[8] Guangdong Fundamental and Applied Basic Research Fund-Joint Fund, Youth Project, 2019A1515110597, Study on the Molecular Mechanism of Curcumol Reversing Lung Adenocarcinoma's Tolerance to TRAIL by Targeting NQO2 Proteins, 2020-01 to 2022-12, 100,000, presided over, completed.

[9] China Postdoctoral Science Foundation, Special Grant, 2020T130252, Functional and Mechanistic Studies on the Promotion of Malignant Proliferation of Colorectal Cancer by uPE1 Protein C20orf24, 2020-08 to 2021-07, 180,000, presided over, completed.

[10] China Postdoctoral Science Foundation, Top Project, 2018M643372, Research on the molecular mechanism of uPE1 protein C20orf112 regulating the stemness of colorectal cancer, 2018-11 to 2021-07, 50,000, presided over, completed.

Authorized Patents of Invention

[1] Application of C20orf112 in the Preparation of Products Promoting the Proliferation of Cancer Cells; Jing Zhang, Yang Wang, Guibin Gao, Qingyu He; Date of Authorization 20230428; Patent for Invention, ZL 202010142168.1

[2] C20orf24 protein deletion mutant and its application; Jing Zhang, Yang Wang, Qingyu He; Date of Authorization 20211203; Patent for Invention, ZL 202010142168.1

[3] Application of Chonglou Saponin I in detecting lysosomes; Authorization date 20220225; Wang Yang, Zhang Jing, He Qingyu; Patent for Invention, ZL 202110312518.9

[4] Application of curcumol and TRAIL in the preparation of anti-tumor combination drug; Qingyu He, Jing Zhang, Yang Wang, Ye Zhou; Authorization Date 20200414; Patent for Invention, ZL 201810802651.0

[5] Application of curcumol in the preparation of NQO2 protein inhibitors; Qingyu He, Jing Zhang, Yang Wang; Authorization date 20210205; Patent for invention, ZL 201911171172.4

[6] Method and application of protein heat stabilization measurement combined with bidirectional stable isotope labeling proteomics for screening drug targets; Qingyu He, Yang Wang, Jing Zhang, Junze Liang; Date of Authorization 20220225; Patent for Invention, ZL 201910043053.4

[7] Phosphorylation of S260 site of hnRNPC protein as a stemness marker for colorectal cancer; Qingyu He, Yang Wang, Jing Zhang; Authorization date 20221206; Patent for invention, ZL 201911377318.0

[8] Application of new Andrographolide in the preparation of RAB5A protein inhibitors; Qingyu He, Yang Wang, Liye Zhong, Jing Zhang; Date of Authorization 20220930; Patent for Invention, ZL 202011195487.5

Courses Taught